Driven by the lack of effective long-term treatments for severe alopecia areata, Prof. Sudip Das and colleagues from Calcutta National Medical College reviewed recent advances in the condition's pathogenesis, genetic triggers, and targeted therapies to guide clinical decision-making. Therefore, the comprehensive review evaluates recent genomic data, diagnostic scoring tools, and therapies—ranging from topical agents to systemic biologics—to update clinical management strategies for alopecia areata. • Diagnostic Tools: The review detailed that the Alopecia Areata Disease Activity Index (ALADIN) and the Alopecia Areata Gene Signature (AAGS) are vital quantitative gene-expression instruments that effectively stratify disease severity and differentiate mild from severe forms. • Inhibitor Efficacy: Analyzing recent therapeutic breakthroughs, the research revealed that oral Janus kinase (JAK) inhibitors yield an impressive 72.4% positive response rate in clinical cohorts, with complete hair regrowth frequently manifesting within 6.7 months. A comprehensive overview on alopecia areata with review on advances in genetics and treatment.